DiaMedica Therapeutics Inc. (DMAC) Stock Score, Valuation & Financial Research

DiaMedica Therapeutics Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for DMAC

DiaMedica Therapeutics Inc. does not currently have a complete Wall Street Score. The stored market price is USD 8.13. These figures are a research snapshot, not a buy or sell recommendation.

What DiaMedica Therapeutics Inc. does

DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

DiaMedica Therapeutics is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. It funds its operations through capital raises and equity offerings to support the research and development of novel recombinant protein therapies for vascular diseases.

Products and services

  • The company is developing DM199, a recombinant form of the human tissue kallikrein-1 (KLK1) protein, intended for the treatment of acute ischemic stroke, preeclampsia, and fetal growth restriction.

Brands and product families

  • DM199 — Lead product candidate for the treatment of acute ischemic stroke, preeclampsia, and fetal growth restriction. Source

Customer types

Clinical trial participants.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturers for the production of its clinical trial drug supplies. Source

Business strengths to evaluate

  • Proprietary recombinant KLK1 protein technology Source

Business risks and research considerations

  • Dependence on third-party clinical trial sites and contract research organizations Source
  • Requirement for additional capital to fund ongoing clinical development Source
  • Uncertainty of regulatory approval for DM199 Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

DMAC financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 8.13
Market capitalization:
438.07M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -37.54M
Free cash flow:
USD -29.1M
Cash:
USD 5.13M
Total debt:
USD 185K
EPS:
USD -0.72

What stands out

  • Free cash flow is USD -29.1M, negative for the stored period.
  • The balance sheet shows USD 5.13M of cash versus USD 185K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 4.94M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for DMAC

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can DMAC fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is DMAC likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for DMAC to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of DMAC's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research DMAC

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.